Reduction in skin cancer diagnoses in the UK during the COVID-19 pandemic

Clin Exp Dermatol. 2021 Jan;46(1):145-146. doi: 10.1111/ced.14411. Epub 2020 Oct 8.

Abstract

The UK healthcare system, including skin cancer departments, has been profoundly affected by the COVID-19 pandemic. Despite service capacity and a worldwide increase in incidence, anecdotal reports suggest a decline in skin cancer diagnoses following COVID-19. To determine if there has been a decrease in skin cancer diagnosis in the UK in the COVID-19 era, we analysed data from the Northern Cancer Network from 23 March 2020 to 23 June 2020 and compared it with the same period in 2019 (pre-COVID). In the COVID period, there was a decrease of 68.61% in skin cancer diagnoses, from 3619 to 1136 (P < 0.01). Surprisingly, skin cancer waiting times were also reduced in the COVID period compared to the pre-COVID period (median of 8 and 12 days, respectively; P < 0.001). Collectively, these data highlight a statistically significant reduction in both skin cancer diagnoses and waiting times during the COVID period.

Publication types

  • Comparative Study

MeSH terms

  • COVID-19 / epidemiology*
  • COVID-19 / virology
  • Clinical Decision-Making
  • Delivery of Health Care / statistics & numerical data*
  • Humans
  • Incidence
  • SARS-CoV-2 / genetics*
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / epidemiology
  • Telemedicine / instrumentation
  • United Kingdom / epidemiology